New Insights into Pathogenesis and Treatment of ANCA-Associated Vasculitis: Autoantibodies and Beyond

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis is a group of rare systemic diseases affecting small-caliber vessels. The damage caused by AAV mainly involves the lung and kidneys. AAV includes three different types: granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). Although the different phenotypic forms of AAV share common features, recent studies have shown that there are significant differences in terms of pathogenetic mechanisms involving both the adaptive and innate immune systems. Advances in our understanding of pathogenesis have enabled the development of immuno-targeted therapies. This review illustrates the characteristics of the various forms of AAV and the new therapies available for this disease that can have lethal consequences if left untreated.

[1]  S. Gumina,et al.  The Double Game Played by Th17 Cells in Infection: Host Defense and Immunopathology , 2022, Pathogens.

[2]  H. Yazici,et al.  2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria sets for three types of antineutrophilic cytoplasmic antibody-associated vasculitis , 2022, Current opinion in rheumatology.

[3]  M. Yamaguchi,et al.  Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Complicated by Thrombotic Microangiopathy with Posterior Reversible Encephalopathy Syndrome Successfully Treated with Eculizumab: A Case Report. , 2022, Modern rheumatology case reports.

[4]  P. Merkel,et al.  2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis , 2022, Annals of the Rheumatic Diseases.

[5]  P. Merkel,et al.  2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis , 2022, Annals of the Rheumatic Diseases.

[6]  P. Merkel,et al.  2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis , 2022, Annals of the Rheumatic Diseases.

[7]  J. Burns,et al.  Global epidemiology of vasculitis , 2021, Nature Reviews Rheumatology.

[8]  B. Rovin,et al.  Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. , 2021, Kidney international.

[9]  I. Alobid,et al.  Response to mepolizumab according to disease manifestations in patients with eosinophilic granulomatosis with polyangiitis. , 2021, European journal of internal medicine.

[10]  G. Guyatt,et al.  2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis , 2021, Arthritis & rheumatology.

[11]  T. Kaneko,et al.  Clinical Features of Patients with Active Eosinophilic Granulomatosis with Polyangiitis Successfully Treated with Mepolizumab , 2021, International Archives of Allergy and Immunology.

[12]  Y. Sheng,et al.  Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Update: Genetic Pathogenesis , 2021, Frontiers in Immunology.

[13]  P. Merkel,et al.  Avacopan for the Treatment of ANCA-Associated Vasculitis. , 2021, The New England journal of medicine.

[14]  M. Strand,et al.  Efficacy and Safety of Reslizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA). , 2021, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[15]  P. Rutherford,et al.  New insights into the epidemiology of ANCA-associated vasculitides in Germany: results from a claims data study. , 2021, Rheumatology.

[16]  A. Gabrielli,et al.  Rituximab for Eosinophilic Granulomatosis with Polyangiitis: a Systematic Review of Observational Studies. , 2021, Rheumatology.

[17]  T. Takeuchi,et al.  Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis: A systematic literature review. , 2020, Autoimmunity reviews.

[18]  P. V. van Daele,et al.  The value of anti-neutrophil cytoplasmic antibodies (ANCA) testing for the diagnosis of ANCA-associated vasculitis, a systematic review and meta-analysis. , 2020, Autoimmunity reviews.

[19]  B. Rovin,et al.  Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis , 2020, ACR open rheumatology.

[20]  M. Strand,et al.  Benralizumab as a steroid-sparing treatment option in eosinophilic granulomatosis with polyangiitis. , 2020, The journal of allergy and clinical immunology. In practice.

[21]  M. Caminati,et al.  Mepolizumab 100 mg in severe asthmatic patients with EGPA in remission phase. , 2020, The journal of allergy and clinical immunology. In practice.

[22]  S. Sartorelli,et al.  Use of Biologics to Treat Relapsing and/or Refractory Eosinophilic Granulomatosis With Polyangiitis: Data From a European Collaborative Study , 2020, Arthritis & rheumatology.

[23]  E. Rhee,et al.  Incidence, Clinical Features, and Outcomes of Late‐Onset Neutropenia From Rituximab for Autoimmune Disease , 2020, Arthritis & rheumatology.

[24]  P. Heeringa,et al.  Mycophenolic acid and 6-mercaptopurine both inhibit B-cell proliferation in granulomatosis with polyangiitis patients, whereas only mycophenolic acid inhibits B-cell IL-6 production , 2020, PloS one.

[25]  A. Vaglio,et al.  Eosinophilic granulomatosis with polyangiitis: understanding the disease and its management. , 2020, Rheumatology.

[26]  L. Guillevin,et al.  Rituximab treatment of ANCA-associated vasculitis , 2020, Expert opinion on biological therapy.

[27]  S. Holdsworth,et al.  Animal Models of ANCA Associated Vasculitis , 2020, Frontiers in Immunology.

[28]  D. D'cruz,et al.  Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines. , 2020, Rheumatology.

[29]  A. Levin,et al.  Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. , 2020, The New England journal of medicine.

[30]  F. Salvador ANCA associated vasculitis. , 2020, European journal of internal medicine.

[31]  J. Pirkle,et al.  Narrative Review of Hypercoagulability in Small-Vessel Vasculitis , 2020, Kidney international reports.

[32]  P. Merkel,et al.  ANCA-associated vasculitis , 2020, Nature Reviews Disease Primers.

[33]  D. Geetha,et al.  ANCA-Associated Vasculitis: Core Curriculum 2020. , 2020, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[34]  W. Koldingsnes,et al.  Increasing incidence and prevalence of ANCA-associated vasculitis in Northern Norway. , 2019, Rheumatology.

[35]  J. Belliere,et al.  Glucocorticoid-free induction regimen in severe ANCA-associated vasculitis using a combination of rituximab and eculizumab. , 2019, Rheumatology.

[36]  C. Vigneau,et al.  The Presence of Renal IgG Deposits in Necrotizing Crescentic Glomerulonephritis Associated with ANCA Is Not Related to Worse Renal Clinical Outcomes , 2019, Kidney Diseases.

[37]  J. Subra,et al.  Complement alternative pathway in ANCA-associated vasculitis: Two decades from bench to bedside. , 2019, Autoimmunity reviews.

[38]  D. Jayne Complement inhibition in ANCA vasculitis. , 2019, Nephrologie & therapeutique.

[39]  Yichun Hu,et al.  Measuring Circulating Complement Activation Products in Myeloperoxidase– and Proteinase 3–Antineutrophil Cytoplasmic Antibody–Associated Vasculitis , 2019, Arthritis & rheumatology.

[40]  L. Fugger,et al.  A plasmid-encoded peptide from Staphylococcus aureus induces anti-myeloperoxidase nephritogenic autoimmunity , 2019, Nature Communications.

[41]  S. Nishio,et al.  The presence of anti-neutrophil extracellular trap antibody in patients with microscopic polyangiitis. , 2019, Rheumatology.

[42]  E. Martins,et al.  Increased renal damage in hypocomplementemic patients with ANCA-associated vasculitis: retrospective cohort study , 2019, Clinical Rheumatology.

[43]  S. Ohlsson,et al.  Neutrophils from ANCA-associated vasculitis patients show an increased capacity to activate the complement system via the alternative pathway after ANCA stimulation , 2019, PloS one.

[44]  D. Jayne,et al.  Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis , 2019, RMD Open.

[45]  Laura Martínez Valenzuela,et al.  T-lymphocyte in ANCA-associated vasculitis: what do we know? A pathophysiological and therapeutic approach , 2019, Clinical kidney journal.

[46]  N. Zeleznik-Le,et al.  NKG2D signaling certifies effector CD8 T cells for memory formation , 2019, Journal of Immunotherapy for Cancer.

[47]  David W. Johnson,et al.  Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. , 2019, Kidney international.

[48]  O. Witzke,et al.  Th17 cells in renal inflammation and autoimmunity. , 2019, Autoimmunity reviews.

[49]  A. Ishizu,et al.  Pathogenesis and therapeutic interventions for ANCA-associated vasculitis , 2018, Nature Reviews Rheumatology.

[50]  Yong-Beom Park,et al.  Low serum complement 3 level is associated with severe ANCA-associated vasculitis at diagnosis , 2018, Clinical and Experimental Nephrology.

[51]  D. Jayne,et al.  B cell therapy in ANCA-associated vasculitis: current and emerging treatment options , 2018, Nature Reviews Rheumatology.

[52]  L. Guillevin,et al.  Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss) , 2018, Seminars in Respiratory and Critical Care Medicine.

[53]  E. Matteson,et al.  Risk of Cardiovascular Disease and Venous Thromboembolism Among Patients With Incident ANCA‐Associated Vasculitis: A 20‐Year Population‐Based Cohort Study , 2018, Mayo Clinic proceedings.

[54]  R. Manz,et al.  Targeting B Cells and Plasma Cells in Autoimmune Diseases , 2018, Front. Immunol..

[55]  Min Chen,et al.  Complement Factor H Inhibits Anti-Neutrophil Cytoplasmic Autoantibody-Induced Neutrophil Activation by Interacting With Neutrophils , 2018, Front. Immunol..

[56]  P. Fu,et al.  Complement regulatory proteins in kidneys of patients with anti‐neutrophil cytoplasmic antibody (ANCA)‐associated vasculitis , 2018, Clinical and experimental immunology.

[57]  V. Papayannopoulos Neutrophil extracellular traps in immunity and disease , 2017, Nature Reviews Immunology.

[58]  A. Vaglio,et al.  Scheduled rituximab maintenance reduces relapse rate in eosinophilic granulomatosis with polyangiitis , 2017, Annals of the rheumatic diseases.

[59]  E. Matteson,et al.  The Epidemiology of Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis in Olmsted County, Minnesota , 2017, Arthritis & rheumatology.

[60]  R. Voll,et al.  Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment: A 36-Month Follow-Up Analysis. , 2017, The journal of allergy and clinical immunology. In practice.

[61]  William H. Yang,et al.  Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial , 2017, The Lancet.

[62]  S. Holdsworth,et al.  ANCA-Associated Vasculitis: Pathogenesis, Models, and Preclinical Testing. , 2017, Seminars in nephrology.

[63]  M. Jadoul,et al.  Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis. , 2017, Journal of the American Society of Nephrology : JASN.

[64]  M. Alba,et al.  Interstital lung disease in ANCA vasculitis. , 2017, Autoimmunity reviews.

[65]  D. Jayne,et al.  Chronic nasal Staphylococcus aureus carriage identifies a subset of newly diagnosed granulomatosis with polyangiitis patients with high relapse rate , 2017, Rheumatology.

[66]  S. Yancey,et al.  Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis , 2017, The New England journal of medicine.

[67]  Hiroyuki Sato,et al.  The influence of the Great East Japan earthquake on microscopic polyangiitis: A retrospective observational study , 2017, PloS one.

[68]  J. Starmer,et al.  Gene-Specific DNA Methylation Changes Predict Remission in Patients with ANCA-Associated Vasculitis. , 2017, Journal of the American Society of Nephrology : JASN.

[69]  A. Vaglio,et al.  Complement blockade in ANCA-associated vasculitis: an index case, current concepts and future perspectives , 2017, Internal and Emergency Medicine.

[70]  R. Watts,et al.  ANCA-associated vasculitis , 2017, Clinical medicine.

[71]  Min Chen,et al.  The functional activities of complement factor H are impaired in patients with ANCA-positive vasculitis. , 2017, Clinical immunology.

[72]  C. Frampton,et al.  Incidence of anti‐neutrophil cytoplasmic antibody‐associated vasculitis before and after the February 2011 Christchurch Earthquake , 2017, Internal medicine journal.

[73]  Richard A Watts,et al.  The incidence, prevalence and mortality of granulomatosis with polyangiitis in the UK Clinical Practice Research Datalink , 2016, Rheumatology.

[74]  C. Demirkesen Approach to cutaneous vasculitides with special emphasis on small vessel vasculitis: histopathology and direct immunofluorescence , 2017, Current opinion in rheumatology.

[75]  A. Schwarting,et al.  Genetics and pathophysiology of granulomatosis with polyangiitis (GPA) and its main autoantigen proteinase 3. , 2016, Molecular and cellular probes.

[76]  T. Schall,et al.  Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study , 2016, PloS one.

[77]  P. Merkel,et al.  EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis , 2016, Annals of the rheumatic diseases.

[78]  W. Szczeklik,et al.  Neurological manifestations in ANCA-associated vasculitis - assessment and treatment , 2016, Expert review of neurotherapeutics.

[79]  G. Pamuk,et al.  The epidemiology of antineutrophil cytoplasmic antibody-associated vasculitis in northwestern Turkey , 2016, Clinical Rheumatology.

[80]  U. Specks,et al.  Diffuse Alveolar Hemorrhage Secondary to Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: Predictors of Respiratory Failure and Clinical Outcomes , 2015, Arthritis & rheumatology.

[81]  P. Merkel,et al.  Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type , 2015, Annals of the rheumatic diseases.

[82]  O. Dekkers,et al.  Genetic variants in ANCA-associated vasculitis: a meta-analysis , 2015, Annals of the rheumatic diseases.

[83]  P. Merkel,et al.  Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg–Strauss) , 2014, Annals of the rheumatic diseases.

[84]  R. Marconi,et al.  First report of FIP1L1-PDGFRα-positive eosinophilic granulomatosis with polyangiitis. , 2015, Rheumatology.

[85]  C. Wang,et al.  Neutrophil extracellular traps can activate alternative complement pathways , 2015, Clinical and experimental immunology.

[86]  M. Klinger,et al.  The kidneys and ANCA-associated vasculitis: from pathogenesis to diagnosis , 2015, Clinical kidney journal.

[87]  D. Roberts,et al.  Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease. , 2015, Journal of autoimmunity.

[88]  P. Ravaud,et al.  Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. , 2014, The New England journal of medicine.

[89]  C. Buzio,et al.  Eosinophilic Granulomatosis with Polyangiitis: An Overview , 2014, Front. Immunol..

[90]  P. Cacoub,et al.  Granulomatosis with polyangiitis (Wegener): clinical aspects and treatment. , 2014, Autoimmunity reviews.

[91]  G. Berry,et al.  T Cell–Macrophage Interactions and Granuloma Formation in Vasculitis , 2014, Front. Immunol..

[92]  R. Falk,et al.  Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease , 2014, Nature Reviews Rheumatology.

[93]  Min Chen,et al.  The interaction between C5a and sphingosine-1-phosphate in neutrophils for antineutrophil cytoplasmic antibody mediated activation , 2014, Arthritis Research & Therapy.

[94]  M. Mahler,et al.  Novel Clinical and Diagnostic Aspects of Antineutrophil Cytoplasmic Antibodies , 2014, Journal of immunology research.

[95]  Min Chen,et al.  Coagulation and Fibrinolysis Index Profile in Patients with ANCA-Associated Vasculitis , 2014, PloS one.

[96]  R. Falk,et al.  B cell-mediated pathogenesis of ANCA-mediated vasculitis , 2014, Seminars in Immunopathology.

[97]  D. D'cruz,et al.  Diagnosis and classification of granulomatosis with polyangiitis (aka Wegener's granulomatosis). , 2014, Journal of autoimmunity.

[98]  T. Schall,et al.  C5a receptor (CD88) blockade protects against MPO-ANCA GN. , 2014, Journal of the American Society of Nephrology : JASN.

[99]  K. Costenbader,et al.  The association between silica exposure and development of ANCA-associated vasculitis: systematic review and meta-analysis. , 2013, Autoimmunity reviews.

[100]  T. Tsuburai,et al.  Decreases in the Numbers of Peripheral Blood Regulatory T Cells, and Increases in the Levels of Memory and Activated B Cells, in Patients with Active Eosinophilic Granulomatosis and Polyangiitis , 2013, Journal of Clinical Immunology.

[101]  Stephan Ripke,et al.  Association of granulomatosis with polyangiitis (Wegener's) with HLA-DPB1*04 and SEMA6A gene variants: evidence from genome-wide analysis. , 2013, Arthritis and rheumatism.

[102]  A. Vaglio,et al.  Eosinophilic granulomatosis with polyangiitis (Churg–Strauss): state of the art , 2013, Allergy.

[103]  F. Moosig,et al.  A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg–Strauss, EGPA): monocentric experiences in 150 patients , 2012, Annals of the rheumatic diseases.

[104]  C. Kallenberg,et al.  Complement is crucial in the pathogenesis of ANCA-associated vasculitis. , 2013, Kidney international.

[105]  P. Merkel,et al.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. , 2013, Arthritis and rheumatism.

[106]  T. Haferlach,et al.  Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. , 2012, The Journal of allergy and clinical immunology.

[107]  Yichun Hu,et al.  High Basal Activity of the PTPN22 Gain-of-Function Variant Blunts Leukocyte Responsiveness Negatively Affecting IL-10 Production in ANCA Vasculitis , 2012, PloS one.

[108]  Panos Deloukas,et al.  Genetically distinct subsets within ANCA-associated vasculitis. , 2012, The New England journal of medicine.

[109]  N. Ortego-Centeno,et al.  Manifestaciones otorrinolaringológicas de las vasculitis sistémicas , 2012 .

[110]  Min Chen,et al.  Propylthiouracil-induced antineutrophil cytoplasmic antibody-associated vasculitis , 2012, Nature Reviews Nephrology.

[111]  Min Chen,et al.  p38MAPK, ERK and PI3K Signaling Pathways Are Involved in C5a-Primed Neutrophils for ANCA-Mediated Activation , 2012, PloS one.

[112]  R. Kolbeck,et al.  Molecular and clinical rationale for therapeutic targeting of interleukin‐5 and its receptor , 2012, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[113]  P. Merkel,et al.  Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis--a meta-analysis. , 2012, Rheumatology.

[114]  M. Radić,et al.  Drug-induced vasculitis: a clinical and pathological review. , 2012, The Netherlands journal of medicine.

[115]  D. Scott,et al.  Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K. , 2011, Rheumatology.

[116]  J. Köhl,et al.  TLR activation enhances C5a-induced pro-inflammatory responses by negatively modulating the second C5a receptor, C5L2 , 2011, European journal of immunology.

[117]  C. Kallenberg Pathogenesis of ANCA-associated vasculitides , 2011, Annals of the rheumatic diseases.

[118]  L. Mouthon,et al.  The Five-Factor Score Revisited: Assessment of Prognoses of Systemic Necrotizing Vasculitides Based on the French Vasculitis Study Group (FVSG) Cohort , 2011, Medicine.

[119]  M. Sanak,et al.  Both Th2 and Th17 responses are involved in the pathogenesis of Churg-Strauss syndrome. , 2011, Clinical and experimental rheumatology.

[120]  I. Bièche,et al.  Interleukin-25: a cytokine linking eosinophils and adaptive immunity in Churg-Strauss syndrome. , 2010, Blood.

[121]  T. Magnuson,et al.  Epigenetic basis for aberrant upregulation of autoantigen genes in humans with ANCA vasculitis. , 2010, The Journal of clinical investigation.

[122]  M. Said Upper Respiratory Tract Symptoms, Renal Involvement and Vasculitis: A Case Report and Review of Wegener Granulomatosis , 2010, Journal of clinical medicine research.

[123]  P. Merkel,et al.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis. , 2010, The New England journal of medicine.

[124]  P. van Paassen,et al.  Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. , 2010, The New England journal of medicine.

[125]  C. Pagnoux Churg-Strauss syndrome: evolving concepts. , 2010, Discovery medicine.

[126]  P. van Paassen,et al.  T cells in ANCA-associated vasculitis: what can we learn from lesional versus circulating T cells? , 2010, Arthritis research & therapy.

[127]  Sharon A Chung,et al.  Microscopic polyangiitis. , 2010, Rheumatic diseases clinics of North America.

[128]  Justine R. Smith,et al.  Ocular disease in patients with ANCA-positive vasculitis , 2009, Journal of ocular biology, diseases, and informatics.

[129]  L. Jacobsson,et al.  Incidence and survival rates in Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. , 2009, Rheumatology.

[130]  P. Monk,et al.  Complement component 5a (C5a). , 2009, The international journal of biochemistry & cell biology.

[131]  Ashkan Emadi,et al.  Cyclophosphamide and cancer: golden anniversary , 2009, Nature Reviews Clinical Oncology.

[132]  R. Sinico,et al.  Churg-Strauss angiitis. , 2009, Best practice & research. Clinical rheumatology.

[133]  S. Nourshargh,et al.  Cardiovascular , Pulmonary and Renal Pathology Experimental Autoimmune Vasculitis An Animal Model of Anti-neutrophil Cytoplasmic Autoantibody-Associated Systemic Vasculitis , 2009 .

[134]  F. Luft,et al.  C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. , 2009, Journal of the American Society of Nephrology : JASN.

[135]  David Steven Scott,et al.  Modification and validation of the Birmingham Vasculitis Activity Score (version 3) , 2008, Annals of the rheumatic diseases.

[136]  L. Mouthon,et al.  Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. , 2008, The New England journal of medicine.

[137]  Min Chen,et al.  Long-term outcomes of patients with propylthiouracil-induced anti-neutrophil cytoplasmic auto-antibody-associated vasculitis. , 2008, Rheumatology.

[138]  J. Zwerina,et al.  Eotaxin-3 is involved in Churg-Strauss syndrome--a serum marker closely correlating with disease activity. , 2008, Rheumatology.

[139]  E. Popa,et al.  Staphylococcal toxic-shock-syndrome-toxin-1 as a risk factor for disease relapse in Wegener's granulomatosis. , 2007, Rheumatology.

[140]  D. Scott,et al.  Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies , 2006, Annals of the rheumatic diseases.

[141]  P. Heeringa,et al.  Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. , 2007, The American journal of pathology.

[142]  P. van Paassen,et al.  Mechanisms of Vasculitis: How Pauci-Immune Is ANCA-Associated Renal Vasculitis? , 2006, Nephron Experimental Nephrology.

[143]  M. Hickey,et al.  Anti-neutrophil cytoplasmic antibodies and effector CD4+ cells play nonredundant roles in anti-myeloperoxidase crescentic glomerulonephritis. , 2006, Journal of the American Society of Nephrology : JASN.

[144]  Laura Pavone,et al.  Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. , 2005, Arthritis and rheumatism.

[145]  C. Kallenberg,et al.  Activation, Apoptosis, and Clearance of Neutrophils in Wegener's Granulomatosis , 2005, Annals of the New York Academy of Sciences.

[146]  E. Lewis,et al.  Pulmonary-renal syndrome in a newborn with placental transmission of ANCAs. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[147]  P. Bansal,et al.  Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement. , 2004, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[148]  D. Roos,et al.  Pathogenesis of diseases associated with antineutrophil cytoplasm autoantibodies. , 2004, Human immunology.

[149]  C. Kallenberg,et al.  The Th1 and Th2 Paradigm in ANCA-Associated Vasculitis , 2003, Kidney and Blood Pressure Research.

[150]  U. Specks,et al.  Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. , 2003, The American journal of medicine.

[151]  J. Stone Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial. , 2003, Arthritis and rheumatism.

[152]  M. González-Gay,et al.  The epidemiology of the primary systemic vasculitides in northwest Spain: implications of the Chapel Hill Consensus Conference definitions. , 2003, Arthritis and rheumatism.

[153]  P. Heeringa,et al.  Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. , 2002, The Journal of clinical investigation.

[154]  R. Falk,et al.  ANCA are pathogenic--oh yes they are! , 2002, Journal of the American Society of Nephrology : JASN.

[155]  C. Kallenberg,et al.  Staphylococcus aureus and Wegener's granulomatosis , 2001, Arthritis research.

[156]  D. Scott,et al.  Epidemiology of vasculitis in Europe , 2001, Annals of the rheumatic diseases.

[157]  M. Daha,et al.  Proteinase 3 enhances endothelial monocyte chemoattractant protein-1 production and induces increased adhesion of neutrophils to endothelial cells by upregulating intercellular cell adhesion molecule-1. , 2001, Journal of the American Society of Nephrology : JASN.

[158]  W. Gross,et al.  Elevated interleukin-4 and interleukin-13 production by T cell lines from patients with Churg-Strauss syndrome. , 2001, Arthritis and rheumatism.

[159]  C. Savage,et al.  Treatment of rolling neutrophils with antineutrophil cytoplasmic antibodies causes conversion to firm integrin-mediated adhesion. , 2000, Arthritis and rheumatism.

[160]  M. Heller,et al.  An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. , 2000, Arthritis and rheumatism.

[161]  S. Sasayama,et al.  Significantly high regional morbidity of MPO-ANCA-related angitis and/or nephritis with respiratory tract involvement after the 1995 great earthquake in Kobe (Japan). , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[162]  M. Ernst,et al.  Granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) but not granulocyte colony‐stimulating factor (G‐CSF) induces plasma membrane expression of proteinase 3 (PR3) on neutrophils in vitro , 2000, Clinical and experimental immunology.

[163]  D. Scott,et al.  Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. , 2000, Arthritis and rheumatism.

[164]  R J Falk,et al.  International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA) , 1999, American journal of clinical pathology.

[165]  W. Koldingsnes,et al.  Severe intestinal involvement in Wegener's granulomatosis: report of two cases and review of the literature. , 1998, British journal of rheumatology.

[166]  C. Gordon,et al.  Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. , 1997, Arthritis and rheumatism.

[167]  C. Kallenberg,et al.  Autoantibodies to myeloperoxidase aggravate mild anti-glomerular-basement-membrane-mediated glomerular injury in the rat. , 1996, The American journal of pathology.

[168]  C. Kallenberg,et al.  Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis , 1996 .

[169]  T. Shibata,et al.  Aggravation of rat nephrotoxic serum nephritis by anti-myeloperoxidase antibodies. , 1995, Kidney international.

[170]  R. Wetsel Expression of the complement C5a anaphylatoxin receptor (C5aR) on non-myeloid cells. , 1995, Immunology letters.

[171]  A. Fauci,et al.  Classics in medicine , 1994 .

[172]  C. Kallenberg,et al.  Antimyeloperoxidase-associated proliferative glomerulonephritis: an animal model , 1993, The Journal of experimental medicine.

[173]  M. Keogan,et al.  Activation of normal neutrophils by anti‐neutrophil cytoplasm antibodies , 1992, Clinical and experimental immunology.

[174]  Guy Hoffman,et al.  Wegener Granulomatosis: An Analysis of 158 Patients , 1992, Annals of Internal Medicine.

[175]  D A Bloch,et al.  The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction. , 2010, Arthritis and rheumatism.

[176]  T. Carey,et al.  Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. The Glomerular Disease Collaborative Network. , 1990, Annals of internal medicine.

[177]  R J Falk,et al.  Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[178]  A. Wiik,et al.  Indirect immunofluorescence examination for IgG-ANCA in sera submitted for the 1st international workshop on ANCA, 1988. , 1989, APMIS. Supplementum.

[179]  A. Fauci,et al.  Suppression of human B lymphocyte function by cyclophosphamide. , 1982, Journal of immunology.